Brain-derived neurotrophic factor and schizophrenia

Jessica L. Gören, PharmD, BCPP¹

How to cite: Gören JL. Brain-derived neurotrophic factor and schizophrenia. Ment Health Clin [Internet]. 2016;6(6):285-8. DOI: 10.9740/mhc.2016.11.285.

Abstract
Schizophrenia is a severe disorder affecting approximately 1% of the population. Historically, alterations of dopaminergic function were considered the primary cause of schizophrenia. However, for many patients, drugs that alter dopaminergic function do not consistently lead to resolution of the symptoms of schizophrenia. Thus, there is an increased interest in pathophysiologic processes that result in altered neurodevelopment and plasticity associated with schizophrenia. Brain-derived neurotrophic factor (BDNF) is a neurotrophin involved in neurogenesis, synaptic plasticity, cognition, and neurotransmission. Genetic polymorphism, expression, and function of BDNF have been implicated in psychiatric diseases, including schizophrenia. This review discusses BDNF, its role in neurologic processes, and the evidence implicating BDNF in schizophrenia.

Keywords: schizophrenia, brain-derived neurotrophic factor, BDNF

Introduction
Schizophrenia is a chronic disorder affecting 1% of the population. Although alterations in dopaminergic function have been found in schizophrenia, administration of dopamine antagonists is ineffective or suboptimal in more than 30% of patients with schizophrenia.¹ Alternate theories of schizophrenia point to neurodevelopmental abnormalities as a potential cause. Brain-derived neurotrophic factor (BDNF) is a neurotrophic factor essential for development of the central nervous system and modulation of neuronal connections that may be involved in the pathophysiology of schizophrenia.

Background
Neurotrophins are a family of proteins involved in the growth and survival of neurons. During brain development, neurotrophins support neuronal growth, differentiation, and survival. Long-term effects of neurotrophins, such as axonal and dendrite growth, synaptic structure and connections, and neuroplasticity, are dependent on gene regulation.² Short-term cytoplasmic effects of neurotrophins influence neuronal differentiation, modulation of neuronal excitability, and synaptic transmission.² In animal models, lack of neurotrophins is associated with decreased synaptic connectivity.³ Thus, neurotrophins appear necessary for the proper function of synapses that may be directly related to symptoms of schizophrenia.³,⁴ Brain-derived neurotrophic factor is the most widely studied neurotrophin and is expressed in the periphery and central nervous system. It is involved in brain development, including neurogenesis, and neuronal differentiation, maturation, and survival.²,³ In the adult brain, BDNF is important for neuronal plasticity, apoptosis, modulation of neurotransmitters, and survival of dopaminergic, cholinergic, and serotonergic neurons, which have been implicated in memory and cognitive changes in schizophrenia.³,⁶ Brain-derived neurotrophic factor also promotes cellular and molecular functions related to neurotransmitter release.³⁴ Aberrant function of BDNF could lead to changes in neuronal cell development,
BDNF and Psychotic Symptoms

Animal models have demonstrated BDNF is important for the development and activation of neurotransmitters associated with psychosis.\textsuperscript{2,7-11} Neurodevelopmental models suggest reduced concentrations of BDNF modify synaptic efficiency and connectivity, which alters neurotransmission and results in signs and symptoms consistent with schizophrenia.\textsuperscript{2,10-13} Models of drug-induced psychosis (ie, phencyclidine, dizocilpine, ibotenic acid) demonstrate decreased BDNF mRNA concentrations are associated with psychotic symptoms.\textsuperscript{9-11} This suggests early life changes in BDNF are associated with impaired neurotransmission and psychotic symptoms later in life.

BDNF and the Environment

Transcription of BDNF is a complex process that involves activation of a multistep signal cascade. When induction of BDNF transcription is activity triggered, only certain mRNA isoforms are produced.\textsuperscript{14-16} Neuronal activity induced by seizures and sensory stimuli through N-methyl-D-aspartate receptor and L-type voltage-gated calcium channels leads to changes in BDNF gene expression through initiation of this activity-triggered transcription signal cascade, which may result in expression of a limited range of mRNA isoforms that increase the risk of developing schizophrenia.\textsuperscript{14-16} Such epigenetic regulation of BDNF expression is consistent with the theory that schizophrenia is a result of both environmental and genetic influences.\textsuperscript{17}

BDNF and Genetics

Progressive changes in brain volume in schizophrenia have been associated with the Val66Met polymorphism of the BDNF gene.\textsuperscript{18,19} The Val66Met polymorphism has also been associated with lower BDNF serum concentrations, which correlates with decreased hippocampal volume.\textsuperscript{18-20} Given the similarities in brain changes associated with schizophrenia and the Val66Met polymorphism, it has been posited that the Val66Met genotype is associated with schizophrenia.\textsuperscript{18-20} However, studies assessing the association of Val66Met polymorphisms with schizophrenia have reported mixed results. One meta-analysis\textsuperscript{21} found that although overall hippocampal volumes were decreased in patients compared with controls, the effect was independent of Val66Met genotype, suggesting BDNF polymorphism may not be a risk factor for decreased hippocampal volume in schizophrenia. This was confirmed in a second meta-analysis,\textsuperscript{22} which also failed to find an association. Conversely, although one meta-analysis reported an association of the Val66Met polymorphism with schizophrenia, another reported an association only in Asian, European, and Chinese populations.\textsuperscript{23,24} In the largest meta-analysis\textsuperscript{24} of 11,480 patients with schizophrenia and 13,490 controls, no association between the Val66Met polymorphism and schizophrenia was found. However, the Val66Met polymorphism may be associated with younger age of onset.\textsuperscript{25-27}

Given BDNF’s role in cognition and memory, it has been proposed that modulation of BDNF expression through the Val66Met genotype could account for cognitive symptoms associated with schizophrenia.\textsuperscript{28} However, data are mixed on this topic. One study\textsuperscript{29} reported an association of the Val66Met polymorphism with impaired cognitive function in bipolar disorder but not schizophrenia. Another study\textsuperscript{30} reported a significant association of the Val66Met polymorphism and cognitive deficits in schizophrenia. Another study\textsuperscript{31} reported the association was gender specific. A meta-analysis\textsuperscript{32} of 12 studies of 1890 patients failed to find an association between the Val66Met allele and cognition.

There appears to be some relationship between the Val66Met polymorphism and schizophrenia. The exact nature of this relationship has yet to be elucidated. It does not seem that the Val66Met polymorphism of the BDNF gene is directly related to the development of schizophrenia.

It is unclear whether a link between the cognitive symptoms of schizophrenia and the Val66Met polymorphism exists. It may be genetic variation is associated with the clinical presentation of schizophrenia, rather than a direct cause.

BDNF as a Biomarker

Postmortem studies\textsuperscript{33,34} of patients with schizophrenia demonstrated increased BDNF expression in the prefrontal cortex and hippocampus. One study\textsuperscript{35} demonstrated decreased BDNF concentrations in the prefrontal cortex compared with matched controls. However, studies of peripheral BDNF concentrations in patients with schizophrenia have reported mixed outcomes. Although most studies report decreased peripheral concentrations of BDNF, other studies\textsuperscript{7,30,36,37} report elevated BDNF concentrations in patients with schizophrenia. Such differences in findings may be related to the nature of the populations studied (eg, medicated versus unmedicated, treatment-naive) or sampling source (eg, serum versus serum protein). A meta-analysis\textsuperscript{7} of 17 studies of 1114 patients with schizophrenia and 970 age-matched controls reported a moderate reduction in peripheral BDNF concentrations in patients with schizophrenia, although the authors note significant heterogeneity in studies. This
BDNF and Antipsychotics

If schizophrenia is truly related to decreased BDNF concentrations, effective treatments would presumably reverse this trend. Therefore, antipsychotic effects on BDNF concentrations have been investigated. Some studies, but not all, have not demonstrated an increase in BDNF following antipsychotic administration. Studies have failed to find an increase in BDNF with second-generation antipsychotics on both chronic and first-episode patients treated for 8 weeks. One meta-regression of 8 studies failed to find an association between antipsychotic dose and BDNF concentrations. However, this meta-regression was likely underpowered to show an association. Another larger meta-regression failed to find an association between antipsychotic dose and BDNF concentrations. Therefore, antipsychotic effects on BDNF concentrations would better reflect BDNF’s role in schizophrenia. However, it is unclear whether peripheral concentrations reflect central nervous system BDNF concentrations. Currently, peripheral BDNF concentrations are not a viable biomarker for schizophrenia.

Conclusions

BDNF appears to be involved in numerous neuronal processes known to be associated with schizophrenia. Several animal models indicate that BDNF plays a role in schizophrenia. However, human data are mixed. Although it appears BDNF is implicated in schizophrenia, the data are far from conclusive as to the exact nature of the relationship or how to leverage this information into the diagnosis or treatment of patients with schizophrenia.

References

1. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23. DOI: 10.1056/NEJMoa0535688. PubMed PMID: 16372203.
2. Favalli G, Li J, Belmonte-de-Abreu P, Wong AH, Daskalakis ZJ. The role of BDNF in the pathophysiology and treatment of schizophrenia. J Psychiatr Res. 2012;46(1):11. DOI: 10.1016/j.jpsychires.2011.09.022. PubMed PMID: 22030467.
3. Nieto R, Kukuljan M, Silva H. BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory. Front Psychiatry. 2013;4:45. DOI: 10.3389/fpsyt.2013.00045. PubMed PMID: 23782335.
4. Buckley PF, Pillai A, Howell KR. Brain-derived neurotrophic factor: findings in schizophrenia. Curr Opin Psychiatry. 2011;24(2):122-7. DOI: 10.1097/YCO.0b013e3283436eb7. PubMed PMID: 22146461.
5. Toll A, Mane A. Brain-derived neurotrophic factor levels in first episode psychosis: a systematic review. World J Psychiatry. 2015;5(1):154-9. DOI: 10.5498/wjp.v5.i1.154. PubMed PMID: 25812665.
6. Angelucci F, Brenè S, Mathè AA. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry. 2005;10(4):345-52. DOI: 10.1038/mp.2005.37. PubMed PMID: 15655562.
7. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry. 2011;16(9):960-72. DOI: 10.1038/mp.2010.88. PubMed PMID: 20733577.
8. Tanaka T, Saito H, Matsuki N. Inhibition of GABAA synaptic responses by brain-derived neurotrophic factor (BDNF) in rat hippocampus. J Neurosci. 1997;17(29):9259-66. PubMed PMID: 9096122.
9. Mattson MP. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci. 2008;1144(1):97-112. DOI: 10.1196/annals.1418.010. PubMed PMID: 19076369.
10. Snigdha S, Neill JC, McLean SL, Sheamar KE, Cuise L, Shahid M, et al. Phencyclidine (PCP)-induced depression in cognitive performance is gender-specific and associated with a reduction in brain-derived neurotrophic factor (BDNF) in specific regions of the female rat brain. J Mol Neurosci. 2011;45(3):337-45. DOI: 10.1007/s12031-010-9447-5. PubMed PMID: 20852970.
11. Aspe PC, Chlan-Fourney J, Juorio AV, Li XM. Brain-derived neurotrophic factor (BDNF) mRNA in rats with neonatal ibotenic acid lesions of the ventral hippocampus. Brain Res. 2002;956(1):126-35. DOI: 10.1016/S0006-8993(02)01376-8. PubMed PMID: 12226855.
12. Lipska BK, Lerman DN, Khaing ZZ, Weinberger DR. The neonatal ventral hippocampal lesion model of schizophrenia: effects on dopamine and GABA mRNA markers in the rat midbrain. Eur J Neurosci. 2003;18(11):3097-104. DOI: 10.1046/j.1460-9568.2003.03047.x. PubMed PMID: 14656305.
13. van Haren NE, Cahn W, Hulshoff Pol HE, Kahn RS. Schizophrenia as a progressive brain disease. Eur Psychiatry. 2008;23(4):245-54. DOI: 10.1016/j.eurpsy.2007.10.013. PubMed PMID: 18539297.
14. Toro CT, Hallak JE, Dunham JS, Leite JP, Sakamoto AC, Guarneri R, et al. The NR1 N-methyl-D-aspartate subunit and brain-derived neurotrophic factor in temporal lobe epilepsy hippocampus: a comparison of patients with and without coexisting psychiatric symptoms. Epilepsia. 2007;48(12):2352-6. DOI: 10.1111/j.1528-1167.2007.01294.x. PubMed PMID: 17913201.
15. Adda N, Numakawa T, Richards M, Nakajima S, Kunugi H. New insight in expression, transport, and secretion of brain-derived neurotrophic factor: implications in brain-related diseases. World J Biol Chem. 2014;5(4):409-28. DOI: 10.4332/wjbc.v5.i4.409. PubMed PMID: 25426265.
16. Stahl S. Stahl’s essential psychopharmacology. 4th ed. New York: Cambridge University Press; 2013.
17. Benarroch EE. Brain-derived neurotrophic factor: regulation, effects, and potential clinical relevance. Neurology. 2015;84(16):1693-704. DOI: 10.1212/WNL.0000000000001507. PubMed PMID: 25837841.
18. Mitchelmore C, Gede L. Brain Derived Neurotrophic Factor: epigenetic regulation in psychiatric disorders. Brain Res. 2014;1586:162-72. DOI: 10.1016/j.brainres.2014.06.037. PubMed PMID: 2523903.

19. Ho BC, Andreasen NC, Dawson JD, Wassink TH. Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia. Am J Psychiatry. 2007;164(12):1890-9. DOI: 10.1176/appi.ajp.2007.07051193. PubMed PMID: 18056245.

20. Harsisser F, Smieskova R, Schmidt A, Lenz C, Walter A, Wittfeld K, et al. BDNF Val66Met polymorphism and hippocampal volume in neuropsychiatric disorders: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2015;55:107-18. DOI: 10.1016/j.neubiorev.2015.04.017. PubMed PMID: 25956254.

21. Kanazawa T, Glatt SJ, Kia-Keating B, Yoneda H, Tsuang MT. Meta-analysis reveals no association of the Val66Met polymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder. Psychiatr Genet. 2007;17(3):165-70. DOI: 10.1097/YPG.0b013e32801da2e2. PubMed PMID: 17471060.

22. Kheiriollahi M, Kazemi E, Ashouri S. Brain-derived neurotrophic factor gene Val66Met polymorphism and risk of schizophrenia: a meta-analysis of case-control studies. Cell Mol Neurobiol. 2016;36(1):1-10. DOI: 10.1007/s10571-015-0229-x. PubMed PMID: 26134369.

23. Gratacos M, Gonzalez JR, Mercader JM, de Cid R, Urretavizcaya E. BDNF Val66Met polymorphism in psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry. 2007;61(7):591-22. DOI: 10.1016/j.biopsych.2006.08.025. PubMed PMID: 17217930.

24. Zhao X, Huang Y, Chen K, Li D, Han C, Kan Q. The brain-derived neurotrophic factor, BDNF Val66Met polymorphism is not associated with schizophrenia: an updated meta-analysis of 11,480 schizophrenia cases and 13,490 controls. Psychiatry Res. 2015;225(1-2):217-20. DOI: 10.1016/j.psychres.2014.11.015. PubMed PMID: 25468644.

25. Numata S, Ueno SI, Iga J, Ashouri S. Brain-derived neurotrophic factor Val66Met polymorphism in schizophrenia is associated with age at onset and intensity of symptoms. Neurosci Lett. 2006;401(1-2):1-5. DOI: 10.1016/j.neulet.2006.02.054. PubMed PMID: 16533563.

26. Zhang XY, Chen DC, Tan YL, Tan SP, Luo X, Zuo L, et al. BDNF polymorphisms are associated with onset schizophrenia and positive symptoms. Schizophr Res. 2016;170(1):41-7. DOI: 10.1016/j.schres.2015.11.009. PubMed PMID: 26603468.

27. Suchaneck R, Owczarek A, Paul-Samodejny M, Kowalczyk M, Kucia K, Kowalski J. BDNF Val66Met polymorphism is associated with age at onset and intensity of symptoms of paranoid schizophrenia in a Polish population. J Neuropsychiatry Clin Neurosci. 2013;25(2):88-94. DOI: 10.1176/appi.neuropsych.11100234. PubMed PMID: 23487199.

28. Savitz J, Solms M, Ramesar R. The molecular genetics of cognition: dopamine, COMT and BDNF. Genes Brain Behav. 2006;5(4):311-28. DOI: 10.1111/j.1601-883x.2005.00163.x. PubMed PMID: 16716201.

29. Rybakowski JK, Borkowska A, Skibinska M, Szczepankiewicz A, Kapelski P, Leszcynska-Rodziewicz A, et al. Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brain-derived neurotrophic factor gene. Psychiatry Clin Neurosci. 2006;60(4):70-6. DOI: 10.1111/j.1440-1819.2006.01462.x. PubMed PMID: 16472361.

30. Zhang XY, Chen DC, Xiu MH, Haile CN, Luo X, Xu K, et al. Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Hum Genet. 2012;131(7):1287-95. DOI: 10.1007/s00439-012-1150-x. PubMed PMID: 22362486.

31. Lu W, Zhang C, Yi Z, Li Z, Wu Z, Fang Y. Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naive patients with schizophrenia. J Mol Neurosci. 2012;47(3):505-10. DOI: 10.1007/s12031-012-9750-4. PubMed PMID: 22477643.

32. Ahmed AO, Mantini AM, Fridberg DJ, Buckley PF. Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia: a meta-analysis. Psychiatry Res. 2015;226(1):1-13. DOI: 10.1016/j.psychres.2014.12.069. PubMed PMID: 25681004.

33. Iritani S, Niizato K, Nawa H, Ikeda K, Emson PC. Immunohistochemical study of brain-derived neurotrophic factor receptor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(5):802-7. DOI: 10.1016/S0278-5846(03)00112-X. PubMed PMID: 12921793.

34. Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K, et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticobasal system of schizophrenic patients. Mol Psychiatry. 2000;5(3):293-300. PubMed PMID: 10884532.

35. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry. 2003;8(6):592-610. DOI: 10.1038/mp.2003.130. PubMed PMID: 12851636.

36. Fernandes BS, Steiner J, Berk M, Molendijk ML, Gonzalez-Pinto A, Turk CW, et al. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol Psychiatry. 2015;20(9):1108-19. DOI: 10.1038/mp.2014.117. PubMed PMID: 25266124.

37. Durany N, Thorne J. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur Psychiatry. 2004;19(6):326-37. DOI: 10.1016/j.eurpsy.2004.06.020. PubMed PMID: 15363470.

38. Pirildar S, Gonul AS, Taneli F, Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(4):709-13. DOI: 10.1016/j.pnpbp.2004.05.008. PubMed PMID: 15276657.

39. Lee BH, Kim YK. Increased plasma brain-derived neurotrophic factor, not nerve growth factor-Beta, in schizophrenic patients before and after risperidone treatment. Neuropsychobiology. 2009;59(1):51-8. DOI: 10.1159/000205518. PubMed PMID: 19270464.

40. Ajami A, Hosseini SH, Taghipour M, Khalilian A. Changes in serum levels of brain derived neurotrophic factor and nerve growth factor-beta in schizophrenic patients before and after treatment. Scand J Immunol. 2014;80(1):36-42. DOI: 10.1111/j.1365-2567.2014.02403.x. PubMed PMID: 24498860.

41. Hori H, Yoshimura R, Yamada Y, Ikenouchi A, Mitoma M, Ida Y, et al. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol. 2007;22(1):21-7. DOI: 10.1097/YIC.0b0133280135593. PubMed PMID: 17159456.

42. Lee AH, Lange C, Ricken R, Hellweg R, Lang UE. Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. J Clin Psychopharmacol. 2011;31(3):334-6. DOI: 10.1097/JCP.0b013e3281895c51. PubMed PMID: 21508862.